Sodium hyaluronate is the sodium salt of hyaluronic acid, a substance naturally found in joint fluid, skin, and connective tissue. It belongs to a group of products used for viscosupplementation (injected into joints to ease osteoarthritis symptoms), ophthalmic surgical support, and dermal/cosmetic applications. It is typically administered by a healthcare professional.

• Therapeutic Class: Viscosupplement / joint lubricant (orthopedics); ophthalmic viscoelastic device; dermal filler component (aesthetics).

• Pharmacological Class: Glycosaminoglycan (naturally occurring polysaccharide).

• Drug Family: Hyaluronic acid derivatives.

• ATC Classification: M09AX01 (Hyaluronic acid) — classification and regulatory category vary by specific product and intended use.

Approved uses: Pain relief in knee osteoarthritis in patients who have not adequately responded to conservative treatment and simple analgesics (viscosupplementation); as a surgical aid during eye procedures such as cataract surgery (ophthalmic viscoelastic use); and as a component of dermal fillers for cosmetic volume restoration.

Commonly used for: Knee osteoarthritis patients seeking symptom relief before considering surgery, and as a supportive product during certain eye surgeries.

Off-label use (only under medical guidance): Sometimes used in other joints (shoulder, hip) outside the specific knee indication, under specialist judgement.

●       Injection (intra-articular, prefilled syringe): commonly available in concentrations such as 1%, 1.5%, or 2% sodium hyaluronate, in various fill volumes depending on the product.

●       Ophthalmic viscoelastic solution: used during eye surgery, in sterile prefilled syringes.

●       Dermal filler formulations: cross-linked hyaluronic acid gels for cosmetic use (a related but distinct product category).

Hyaluronic acid is a natural component of joint (synovial) fluid, where it provides lubrication and shock absorption. In osteoarthritis, the joint's natural hyaluronic acid becomes thinner and less effective. Injecting sodium hyaluronate directly into the joint aims to restore some of this natural lubricating and cushioning quality, which may help reduce pain and improve movement.

• Standard dose (knee viscosupplementation): Administered as a course of intra-articular injections, typically ranging from a single injection to 3-5 weekly injections, depending on the specific product used.

• Condition-wise dose: The exact number of injections and volume per injection depends on the manufacturer's specific product formulation; not interchangeable between brands without medical guidance.

• Route: Intra-articular injection (directly into the joint), performed by a trained healthcare professional under sterile conditions.

• Missed dose: Rescheduled by the treating clinician as part of the injection course.

• Overdose: Not typically applicable, as this is a clinician-administered procedure rather than a self-dosed medicine.

• Common: Temporary pain, swelling, warmth, or redness at the injection site.

• Serious: Rarely, significant joint swelling (acute local inflammatory reaction), infection at the injection site, or an allergic reaction.

• Emergency symptoms: Signs of joint infection (increasing redness, warmth, fever), severe swelling, or signs of a serious allergic reaction (difficulty breathing, widespread rash).

• Recovery advice: Mild injection-site discomfort typically settles within a day or two; resting the joint briefly after injection and applying a cold pack can help with any temporary swelling.

• Pregnancy: Limited specific data for joint injections; used only if clearly needed.

• Breastfeeding: Limited specific data; discussed with the treating doctor.

• Liver disease: Not a primary concern for locally injected joint products; no specific restriction generally noted.

• Kidney disease: Not a primary concern for locally injected joint products.

• Elderly: Commonly used in this age group, as osteoarthritis is more prevalent with age.

• Children: Not typically used for joint viscosupplementation in children; osteoarthritis-related use is an adult indication.

●       Not typically associated with significant systemic drug interactions, as it acts locally within the joint or surgical field rather than being absorbed into general circulation in large amounts.

●       Should not be injected into a joint that has active skin infection, joint infection, or significant inflammation at the injection site.

●       Caution advised in patients with known allergy to hyaluronan-based products or avian-derived proteins, depending on the manufacturing source of the specific product.

●       Assessment of the injection site for signs of infection or excessive swelling after each injection.

●       Symptom tracking (pain, function) to assess whether the treatment course is providing benefit.

●       Review for known allergies to hyaluronan-based products before starting a course.

Intra-articular corticosteroid injections, oral NSAIDs, and other conservative osteoarthritis management options (different mechanism, often tried before or alongside viscosupplementation).

Sometimes formulated in combination with chondroitin sulfate for joint injections; generally used as part of a broader osteoarthritis management plan that also includes weight management, exercise, and analgesics.

●       Osteoarthritis / Joint Pain Management

●       Viscosupplementation Products

●       Ophthalmic Surgical Aids

1. World Glaucoma Day 

2. 5 Myths About Glaucoma

3. Frequently Asked Questions About Glaucoma

4. January is National Glaucoma Awareness Month

5. Difference Between Osteoarthritis And Rheumatoid Arthritis

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805636/

2. https://www.aetna.com/cpb/medical/data/100_199/0179.html

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.